← Back to Clinical Trials
Recruiting Phase 4 NCT07436156

NCT07436156 SUMMIT RISE Study of Acute Ischemic Stroke Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07436156
Status Recruiting
Phase Phase 4
Sponsor Route 92 Medical, Inc.
Condition Acute Ischemic Stroke
Study Type INTERVENTIONAL
Enrollment 500 participants
Start Date 2026-02-12
Primary Completion 2029-05-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Route 92 Medical Reperfusion Systems

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.

This trial targets 500 participants in total. It began in 2026-02-12 with a primary completion date of 2029-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

SUMMIT RISE Study of Acute Ischemic Stroke Patients

Eligibility Criteria

Inclusion Criteria: * Acute ischemic stroke patient initially treated (first pass) with a Route 92 Medical Reperfusion System * Informed consent completed and documented within 72 hours following thrombectomy procedure * Endovascular treatment initiated (defined as time of groin puncture) within 8 hours from time last known well * Age ≥ 18 years Exclusion Criteria: * None

Contact & Investigator

Central Contact

Renee Kochevar Vice President, Clinical Research, PhD, ALM

✉ reneek@r92m.com

📞 650-581-1179

Frequently Asked Questions

Who can join the NCT07436156 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07436156 trial and what does that mean for participants?

Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.

Is NCT07436156 currently recruiting?

Yes, NCT07436156 is actively recruiting participants. Contact the research team at reneek@r92m.com for enrollment information.

Where is the NCT07436156 trial being conducted?

This trial is being conducted at West Jordan, United States.

Who is sponsoring the NCT07436156 clinical trial?

NCT07436156 is sponsored by Route 92 Medical, Inc.. The trial plans to enroll 500 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology